Component

Nuchido TIME+ multicomponent preparation in the 2024 trial

Nuchido TIME+ multicomponent preparation in the 2024 trial

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.

    Nuchido TIME+ multicomponent preparation in the 2024 trial → Human CD38 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Multicomponent preparation", "comparator": "Study baseline/placebo comparisons", "endpoint": "PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    PBMC protein assays; 28-day intervention.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial.
    primary_references
    The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0
    source_locator
    Reviewed reference api-human-combined-cd38-null; Protein amount is not enzyme activity; this does not measure direct apigenin occupancy or CD38 inhibition.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 508–514

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · PBMC protein assays; 28-day intervention. · Recorded from source · Recorded from source

    ### api-human-combined-cd38-null PBMC CD38 protein abundance did not change detectably during the 2024 combined-product trial. Protein amount is not enzyme activity; this does not measure direct apigenin occupancy or CD38 inhibition. Model and exposure: PBMC protein assays; 28-day intervention. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  2. The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.

    Nuchido TIME+ multicomponent preparation in the 2024 trial → Circulating NAD content Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Multicomponent preparation", "comparator": "Baseline and placebo comparisons reported by the study", "endpoint": "The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.", "effect_direction": "no_detected_change", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Seventeen-person subset; stored samples and missing participants.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial.
    primary_references
    The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0
    source_locator
    Reviewed reference api-human-combined-lcms-null; Matched reduction of the main assay sample also lost significance. Sample size, selection, storage and assay identity limit comparison.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 500–506

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Seventeen-person subset; stored samples and missing participants. · Recorded from source · Recorded from source

    ### api-human-combined-lcms-null The smaller LC-MS subset did not show a statistically significant NAD+ treatment effect in the same human trial. Matched reduction of the main assay sample also lost significance. Sample size, selection, storage and assay identity limit comparison. Model and exposure: Seventeen-person subset; stored samples and missing participants. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  3. The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.

    Nuchido TIME+ multicomponent preparation in the 2024 trial → Whole-blood NAD+ plus NADH assay signal Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Nuchido TIME+ for 28 days", "comparator": "The active-arm baseline", "endpoint": "The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Randomized double-blind crossover; 26 completed, 23 in the main assay analysis.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay.
    primary_references
    The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0
    source_locator
    Reviewed reference api-human-combined-nad; The Methods describe total NAD+ plus NADH, despite NAD+ terminology elsewhere. Main P=0.007. This is not an isolated-apigenin trial or demonstrated slowing of aging.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 492–498

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Randomized double-blind crossover; 26 completed, 23 in the main assay analysis. · Recorded from source · Recorded from source

    ### api-human-combined-nad The 2024 multicomponent trial reported a 26.5% increase from baseline at day 28 in its main whole-blood NAD assay. The Methods describe total NAD+ plus NADH, despite NAD+ terminology elsewhere. Main P=0.007. This is not an isolated-apigenin trial or demonstrated slowing of aging. Model and exposure: Randomized double-blind crossover; 26 completed, 23 in the main assay analysis. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

  4. The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.

    Nuchido TIME+ multicomponent preparation in the 2024 trial → Human nicotinamide phosphoribosyltransferase / NAMPT Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_contrast
    {"intervention": "Multicomponent preparation", "comparator": "Study baseline comparison", "endpoint": "The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
    experimental_model
    Human crossover trial; multicomponent preparation.
    interpretation_status
    Recorded from source with stated access limits; ungraded, not independent replication.
    limitations
    Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
    nutrient_topic
    Apigenin collection; exact intervention and molecular form govern interpretation. · Apigenin
    plain_language
    The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance.
    primary_references
    The use of a systems approach to increase NAD<sup>+</sup> in human participants. | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0
    source_locator
    Reviewed reference api-human-combined-nampt; Individual ingredient causality and enzyme flux were not isolated.

    Apigenin: detailed mechanisms of action (reviewed 10 October 2026) · lines 516–522

    AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · Human crossover trial; multicomponent preparation. · Recorded from source · Recorded from source

    ### api-human-combined-nampt The combined-product study reported increased PBMC NAMPT and SIRT1 protein abundance. Individual ingredient causality and enzyme flux were not isolated. Model and exposure: Human crossover trial; multicomponent preparation. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: The use of a systems approach to increase NAD<sup>+</sup> in human participants. | 2024 | https://pubmed.ncbi.nlm.nih.gov/38302501/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC10834541/ | https://doi.org/10.1038/s41514-023-00134-0 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.